RESEARCH ARTICLE

Enhanced ZNF521 expression induces an aggressive phenotype in human ovarian carcinoma cell lines

Stefania Scicchitano ID1*, Ylenia Montalcini ID1*, Valeria Lucchino2, Valentina Melocchi ID3, Valerio Gigantino4, Emanuela Chiarella1, Fabrizio Bianchi3, Alessandro Weisz4,5, Maria Mesuraca ID1*

1 Laboratory of Molecular Haematopoiesis and Stem Cell Biology, Department of Experimental and Clinical Medicine, University Magna Graecia, Catanzaro, Italy, 2 Laboratory of Stem Cell Biology Department of Experimental and Clinical Medicine University Magna Graecia, Catanzaro, Italy, 3 Unit of Cancer Biomarkers, Fondazione IRCCS–Casa Sollievo Della Sofferenza, San Giovanni Rotondo (FG), Italy, 4 Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi (SA), Italy, 5 Genome Research Center for Health, University of Salerno Campus, Baronissi (SA), Italy

* These authors contributed equally to this work.

☯ scicchitano@unicz.it (SS); mes@unicz.it (MM)

Abstract

Epithelial ovarian carcinoma (EOC) is the most lethal gynecological tumor, that almost inevitably relapses and develops chemo-resistance. A better understanding of molecular events underlying the biological behavior of this tumor, as well as identification of new biomarkers and therapeutic targets are the prerequisite to improve its clinical management. ZNF521 gene amplifications are present in >6% of OCs and its overexpression is associated with poor prognosis, suggesting that it may play an important role in OC. Increased ZNF521 expression resulted in an enhancement of OC HeyA8 and ES-2 cell growth and motility. Analysis of RNA isolated from transduced cells by RNA-Seq and qRT-PCR revealed that several genes involved in growth, proliferation, migration and tumor invasiveness are differentially expressed following increased ZNF521 expression. The data illustrate a novel biological role of ZNF521 in OC that, thanks to the early and easy detection by RNA-Seq, can be used as biomarker for identification and treatment of OC patients.

Introduction

Epithelial ovarian carcinoma is the leading cause of gynecological cancer-related mortality, with 295,000 new cases and 184,000 deaths worldwide in 2020 [1]. Due to the lack of effective screening programs two-thirds of patients with OC are diagnosed with advanced disease. Despite a generally good response to surgery and first-line chemotherapy, OC almost inevitably relapses in different peritoneal sites and develops chemo-resistance. Only 45% of OC-affected women are likely to survive for five years, compared to 89% of breast cancer patients [2,3]. Despite increased radicality of debulking surgery and modifications of conventional...
chemotherapies there have been only modest gains for overall survival (OS) in OC in the last decades [4]. Based on their histological and morphological classification OC can be divided in serous, mucinous, endometrial, clear cells and transitional cells (depending on the tissue of origin involved). Moreover, OCs can be divided in type I (low-grade tumor with BRAF and KRAS mutations) or type II (high-grade tumor with a variety of mutations including HOX, PTEN, KRAS, AKT1, BRCA1/2 genes) [5–10] and various dysregulated mechanisms underlying the pathology [11–13]. An important therapeutic target in OC may be represented by a subpopulation of cells defined as ovarian cancer stem cells (OCSCs) [14] and considered a key factor in cancer initiation, relapse and resistance to therapy [15,16]. The stem cell-associated transcription co-factor, zinc finger protein 521 (ZNF521) is a transcription factor abundant in OC, where a high expression is associated with poor prognosis [17,18]. ZNF521 has been recently included in a list of top 15 genes associated to poor survival in serous cystadenocarcinomas [19]. A significant number of gene amplifications for ZNF521 are detected in ovarian cancers (~6%) [20]. This association with oncogenesis with a role in control of HSCs (Hematopoietic Stem Cells) [21], LSCs (Leukemic Stem Cells) [22–25] and in iNSCs (immortalized Neural Stem Cells) [26–28] as well as in mesenchymal differentiation [29–34], involves ZNF521 in the control of the Stem Cells (SCs) compartment and in Cancer Stem Cells (CSCs). ZNF521 has also been implicated in miRNA regulation [35] where miR-9, via targeting Zfp521 (murine ortholog to human ZNF521), could promote the neural differentiation of mouse bone marrow mesenchymal stem cells (MSCs) [36]. It is notable that breast and ovarian cancers with BRCA1 mutations are inhibited by miR-9 [37]. Regulation of ZNF521 was also found in gastric cancer cells by miRNA-204-5p [38] and in hepatocellular carcinoma by miR-802 [39]. Additionally, in ovarian cancer an integration analysis of microRNA and mRNA gave a positive association of ZNF521 with the miR34-family and miR133b [18].

As the mortality rate of this tumor has improved only marginally over the past decades, a better understanding of the molecular events that drive its development, maintenance and progression, and the identification of new biomarkers and therapeutic targets, are paramount to improve OC treatment and hence its prognosis. In this study the role of ZNF521 is investigated in the regulation of human ovarian carcinoma cells.

### Materials and methods

#### Cell lines and culture conditions

The differentiated papillary human ovary cystoadenocarcinoma cell line HeyA8, the human desmoplastic cerebellar medulloblastoma DA0Y cells and the human embryonic kidney HEK293T cells were cultured in DMEM. The human ovarian adenocarcinoma cell line ES-2, the acute monocytic leukemia THP1 cells and the lymphoblastoid B (multiple myeloma) IM9 cells were cultured in RPMI. Cell culture medium are supplemented with 10% fetal bovine serum, 50U of penicillin and 50μg of streptomycin/ml (Thermo Fisher Scientific, Milan, Italy) and cell lines were maintained at 37°C in 5% CO₂.

#### Transfection and transduction of cell lines

Lentiviral production was carried out in 100 mm tissue culture plates, where the cell line HEK293T were transfected with 10μg of plasmid for FUIGW (control vector) or FUIGW-ZNF521 [40] plus lentiviral packaging plasmids (2μg of pCMV-ΔVSVG and 10μg of pCMV-deltaR8-91), using the calcium phosphate method. Lentiviral media were collected at 24, 48 and 72 hours after transfection and supplemented with 6μg/ml of polybrene [41] and ovarian carcinoma cell lines HeyA8 and ES-2 were stably transduced with the control vector FUIGW or FUIGW-ZNF521. Three rounds of transduction were performed by centrifuging
the cells with lentivirus at 3200 rpm at 32˚C for 50min. Cells were 70–80% positive for the transgene EGFP by FACS analysis and stably expressed the ZNF521 protein. The transduction was performed in three independent experiments and cells were further sorted for EGFP giving a homogeneous population over 90% positive.

**Proteins extracts and Western blotting**

HeyA8 and ES-2 cells were processed for nuclear and cytoplasmic extracts. Cells were scraped, resuspended in hypotonic lysis buffer 10mM HEPES pH7.9, 10mM KCl, 0.1mM EDTA, protease inhibitors (P8849, Sigma-Aldrich) and phosphatase inhibitor cocktails 2 and 3 (P0044, P5726, Sigma-Aldrich) and incubated on ice for 20 min. After the addition of 0.25% Igepal-630 (NP40) (Sigma-Aldrich), samples were centrifuged at 3000 rpm for 5 min and supernatants containing the cytoplasmic extracts were recovered. Nuclear pellets were resuspended in 20mM HEPES pH7.9, 0.4M NaCl, 1mM EDTA with protease and phosphatase inhibitors. After three cycles of vortex and ice, samples were centrifuged at 12000 rpm for 20 min and the supernatants containing the nuclear extracts were collected.

Proteins were separated on 4–12% NuPAGE Novex Bis-Tris Protein gradient polyacrylamide gels (Thermo Fisher Scientific) and blotted onto nitrocellulose. Membranes were quenched with 5% blotto (BioRad) [42] and the proteins detected with: rabbit anti-ZNF521 (EHZF S15 sc-84808, Santa Cruz Biotechnology, DBA, Milan, Italy) at 1:1000, rabbit anti-HDAC1 (H3284, Sigma) 1:10000. Secondary rabbit HRP antibody at 1:2000 (65–6120 Thermo Fisher Scientific) was detected by the ImmunoCruz Western blotting luminal reagent (sc-2004, Santa Cruz, Biotechnology) and exposure to autoradiographic film (GE Healthcare, Milan, Italy).

**Cell proliferation assay**

Transduced cells (HeyA8 and ES-2) were seeded into 6 well plates at 2.0x10^5 cells/well in complete DMEM or RPMI respectively. Every 48 hours cells were trypsinized, counted and replated at 2.0x10^5/well. The average of three independent cell counts, normalized to account for the dilutions performed in the individual cultures at each replating, was plotted against time to obtain a cumulative growth curve for each cell population.

The growth of HeyA8 was also evaluated using the Real-Time Glo MT Cell Viability Assay (Promega, Milan, Italy) kit, which allows the evaluation of cell proliferation based on their ATP consumption. The cells were plated in 96 wells and then the substrate and the enzyme are added in a 1:1 ratio. The plate was then incubated at 37˚C and the readings (GloMax Explorer, Promega) taken at 0, 24 and 48 hours of growth.

ES-2 proliferation was also measured by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt; MTS(a)] colorimetric assay. Cells were seeded at 5.0x10^2 per well in 96-well plates in DMEM 10% FBS and assayed after 24, 48 and 72 hours of incubation. At each time point, 20μl of MTS solution were added to the wells. After 4 hours of incubation at 37˚C the absorbance, which is proportional to the number of viable cells, was measured at λ = 490 nm (GloMax Explorer, Promega). All the experiments were performed in triplicate.

**Clonogenicity assay**

The transduced cells are trypsinized, counted and resuspended in a medium containing DMEM F12 (GIBCO, Milan, Italy), L-glutamine (Thermo Fisher Scientific) 1%, Pen/Strep (Thermo Fisher Scientific) 1%, B27 (GIBCO) 50x, 20ng/ml hEGF (PeproTech, DBA, Milan, Italy), 2 ng/ml hFGFb (PeproTech). For ES-2 cells 10μg/ml of insulin (Sigma-Aldrich, Milan,
Italy) and 4 μg/ml of heparin (Sigma-Aldrich) are added and plated in ultra-low attachment 6 wells (Corning Inc., Milan, Italy). HeyA8 were plated at a concentration of 3.0x10^4 cells/well and ES-2 at concentration of 4.5x10^4 cells/well. After 7 days spheres formation was observed, the cell number for every culture was calculated and the size of spheres were estimated from acquired images (at 10x magnification) by ImageJ 1.51j8. All the experiments were performed in triplicate.

Wound healing assay–migration assay

Transduced cells were counted, seeded at the same density and cultured until >90% confluence in 6 well plates in appropriate medium with 10% FBS and then in DMEM or RPMI with reduced serum 0.5% FBS to block their proliferation. After 24 hours the monolayer of cells was scratched with a sterile 200μl pipet tip, washed with PBS 1X and incubated at 37˚C in DMEM 10% FBS [43] Images were captured by phase contrast microscopy at 10x magnification, at the beginning and at regular intervals during cell migration. The migration of the cells was analysed and quantified by ImageJ 1.51j8. Experiments were performed in triplicate.

Next generation sequencing–total RNA-Seq

RNA concentration was determined by using Quant-IT RNA Assay Kit-High Sensitivity and a Qubit Fluorometer (Life Technologies) and its quality and integrity assessed with the Agilent 4200 Tapestation System (Agilent Technologies). Total RNA–seq procedures were performed as described previously [44]. Indexed libraries were prepared using 1 μg of total RNA in technical and biological triplicate for each sample as starting material, with a TruSeq Stranded Total RNA Sample Prep Kit (Illumina Inc.). Libraries were sequenced (paired-end, 2x75 cycles) at a concentration of 8 pM/lane on NextSeq 500 platform (Illumina Inc.) [45]. Aliquots of the amplified RNA samples used for RNA-Seq remained available to be used to confirm by qRT-PCR the differential expression of selected genes.

Fastq files were aligned to the hg38 genome assembly using STAR [46]. STAR gene counts were normalized applying the median of ratios method implemented in DESeq2 R package [47]. Briefly, the normalization process implies different steps: i) for each gene, a pseudo-reference sample is created and is equal to the geometric mean across all samples; ii) for every gene in a sample and for each sample, the ratios sample/ref are calculated; iii) the median value of all ratios for a given sample is taken as the normalization factor (size factor) for that sample; iv) for each gene in each sample the normalized count values is calculated dividing each raw count value by the sample’s normalization factor.

For differential gene expression (DEG) analysis, we applied DESeq2 R package to normalized counts.

Heatmaps were generated using Cluster 3.0 for Mac OS X (C Clustering Library 1.56, Tokyo, Japan) with uncentered correlation and centroid linkage, and Java TreeView software environment (version 1.1.6r4; http://jtreeview.sourceforge.net).

Differentially expressed genes were used as input for the Molecular Signature Database Investigate gene sets analysis [48].

Expression analysis by qRT-PCR

cDNA was synthesized using SuperScript III reverse transcriptase at 42˚C and 2.5μM random hexamers (Thermo Fisher Scientific) from 1μg RNA previously prepared with Tri Reagent (Sigma-Aldrich) and verified by the NanoDrop 2000/2000c Spectrophotometer (Thermo Fisher Scientific) [49]. One cycle of 3 min at 95˚C was followed by 45 cycles of 10 sec at 95˚C, 10 sec at 60˚C and 10 sec at 72˚C, finishing with a melting curve, amplified with the iQ™
SYBR® green super mix (BioRad, Milan, Italy) using the qRT-PCR amplifier QuantStudio3 (Applied Biosystems, Milan, Italy).

Analysis of gene expression was calculated as \(2^{-\Delta\Delta C_t}\) and normalized for the housekeeping gene (GAPDH). Primers used in this study were as follows (5'-3'):

- h-ZNF521 were previously described [50];
- h-CTSK-fwd CAGGGTCAGTGTGGTTCCTG,
- h-CTSK-rev CCCCCGTCTTTCTGACATA;
- h-RB1CC1 fwd TTCCACTGTGGAGCTGCTAA,
- h-RB1CC1 rev CATCTGCGTATCTGGGAC;
- h-AIMP1-fwd ACAGCAGTAACAACCCGTATCTTTCTGG,
- h-AIMP1-rev CTATGGCTTGAGTGCGCACTTCC;
- h-PIBF1-fwd CTTACAAAGATTGAGAATGGGAGG,
- h-PIBF1-rev AATTCCTGATATTTGTGCGATCT;
- h-FXYD5-fwd TCCCACGTAGACACCCAGA,
- h-FXYD5 rev AAACACCAGTGCGTTGAGG;
- h-HMMR-fwd ACCAATCAAGCAACACGGAGG,
- h-HMMR-rev CCTGAGCTGCACCATGTTCATT;
- h-SAMD9-fwd GGGAACATCCCTGGCTATGCAC,
- h-SAMD9-rev CGTATTCCTGACGGTTCATTGCC;
- h-GAPDH-fwd CACCATCTTCCAGGAGGAG,
- h-GAPDH-rev TCACGCCCACAGTTTCCCCGGA.

Experiments were performed in triplicate.

**Statistical analysis**

The student’s t-test assuming unequal variances between two samples was used to determine the significant differences (\(p < 0.05\), \(p < 0.01\), \(p < 0.001\), \(p < 0.0001\)).

**Results**

**Enforced expression of ZNF521 enhances growth of ovarian carcinoma cell lines**

ZNF521 is expressed in ovary and ovarian cancers [18] and mutations of its gene (almost invariably amplifications) are present in >6% of OCs (S1A Fig) [20]. Increased expression of ZNF521 was found associated with a poor prognosis in OC patients [17–19]. Analysis of a public genomic database [51] comprising 655 OC patients confirmed an adverse prognosis for patients with ZNF521-high OCs (S1B Fig) [52].

To assess whether the modulation of ZNF521 expression could affect some biological characteristics of OC cells the mRNA levels of ZNF521 for HeyA8 and ES-2 OC cells were quantified by qRT-PCR and compared to that of THP1 cells, DAOY cells and of IM9 that, respectively, express very high, intermediate and very low levels of ZNF521 (Fig 1A). The
HeyA8 and ES-2 cell lines, were stably transduced with two different lentiviral vectors: FUIGW (carrying only the EGFP) or FUIGW-ZNF521 (expressing the ZNF521 cDNA fused to 3xFLAG tag and EGFP) and immunoblot analysis as well as qRT-PCR confirmed a significant increase of ZNF521 expression (Fig 1B and 1C).

Cell growth was investigated in adherent conditions and was measured by cumulative cell numbers (Fig 2A and 2B), MT (Fig 2C) and MTS assays (Fig 2D). In HeyA8 (Fig 2A and 2C), overexpression (OE) of ZNF521 induces a significant (p<0.01) increase in cell growth both at 48h (~1.5-fold increase; 1.06x10^5 ZNF521 vs 7.30x10^4 CTL cells) and after 8 days (~2-fold; 6.96x10^7 RLU in ZNF521 vs 3.4x10^7 RLU in CTL cells; MT assay) (Fig 2B and 2D). Similarly, exogenous ZNF521 expression in ES-2 increased cellular growth at 48h and up to 72 hours (~1.2-fold; 0.905 OD ZNF521 vs 0.745 OD CTL; MTS assay), and after 8 days (2.4-fold; 3.12x10^7 ZNF521 vs 1.3x10^7 CTL).

**ZNF521 improves the migration ability of human ovarian cell lines**

The cell migration and invasion of ZNF521-overexpressing and CTL cells was investigated by wound-healing assay. Cells were plated and grown to confluence, in 6 well plates, and then starved for 24 hours. When cell confluence approximately reached 90%, a longitudinal wound was done using a sterile tip. Cells cultures were observed at regular time intervals, monitoring the extent of the healing of the wound. Both ZNF521-overexpressing cell lines displayed a ~2-fold increase in wound healing capacity (Fig 3) compared to CTL cells.

**ZNF521 enhances clonogenicity of HeyA8 and ES-2 cells**

The proliferation of HeyA8 and ES-2, ZNF521-overexpressing or CTL cells was assessed in anchorage-independent conditions to test their ability to form spheroids as readout for enrichment in CSC subpopulation in OC cell lines.
Overall, ZNF521-overexpressing cells showed a greater number of spheroids and of cells forming spheres (Fig 4A, 4B, 4D and 4E) compared to the controls which confirmed an
enrichment in CSCs. The average areas of spheres, from images of cultures acquired by phase contrast microscopy at 10x, were calculated for 50 spheres in each culture by ImageJ 1.51j8. Notably, ZNF521 transduced cell lines formed larger spheres than the controls (Fig 4C and 4F).

ZNF521 over-expression reprograms the transcriptome of HeyA8 and ES-2 cells

Since ZNF521 is a transcription co-factor we then sought at the transcriptome of OC cell lines upon ZNF521 expression modulation. RNA-Seq analysis of both ES-2 and HeyA8 cell lines, ZNF521-OE or CTL, revealed that ZNF521 overexpression induced a large transcriptional reprogramming involving a total of 1375 and 742 differentially expressed genes (p<0.05), respectively (Fig 5A). Furthermore, Molecular Signature Database (MSigDB) focused on hallmark gene sets (see Methods) scored the enrichment of 4 hallmarks related to cancer proliferation (i.e., E2F targets, EMT, G2M checkpoint and mitotic spindle) both in HeyA8 and in ES-2 cell lines (Fig 5B and 5C), which is in line with previously described enhanced proliferation and migration of HeyA8 and ES-2 cells upon ZNF521 overexpression (Figs 2 and 3). Yet, a total of 106 genes were found overlapping between the 1375 and 742 differentially expressed genes in ZNF521-OE cells (p<0.0001, Fisher’s exact test; Fig 5D). Of these, 10 genes previously described to be associated to tumour growth, metastasis, cell migration and proliferation, were found consistently down- or up-modulated in ZNF521-OE cells vs CTLs (Fig 5E). Lastly,
Fig 5. Differentially expressed genes (DEGs) by ZNF521 in hOC cell lines. (A) Hierarchical clustering of the 1375 and 742 differentially expressed genes (p<0.05) in HeyA8 and ES-2 cells, respectively. Molecular Signatures Database (MSigDB) analysis of HeyA8 (B) and ES-2 (C). (D) Size of dots represents the inverse logarithm (base 10) of statistical significance (FDR q-value) as per the legend. X-axes, fraction (k/K) of overlapping genes (k) in each Gene Set with the total number of genes represented in the specific hallmark (K). In bold, commonly enriched hallmark gene sets. Venn diagram analysis of the 1375 genes differentially expressed in
qRT-PCR analysis of 7 out of 10 genes confirmed their trend of regulation as shown in Fig 6 (A: HeyA8, B: ES-2) in both OC cell lines.

Discussion

Ovarian carcinoma represents an important cancer-related cause of death in women, even considering that the overall survival has only modest advantage from radical debulking surgery and conventional chemotherapy [4]. The major unresolved clinical problems include malignant progression and rapid emergence of drug resistance against conventional chemotherapy. In this regard, novel strategies are warranted based on molecularly targeted therapies directed against components of specific signaling pathways required for tumour development and progression [53]. Additionally, identification of biomarkers with functional and prognostic significance, may greatly aid early diagnosis and allow timely implementation of therapeutic strategies. Profiling of 157 advanced stage serous ovarian cancers, ZNF521 (known regulator of the homeostasis in stem cells compartment and in cancer [18,22–28]) results in a set of 86-genes with significant poor overall survival profiles [17]. In exosomes derived from Bone Marrow Stromal Cells (BMSCs), ZNF521 was identified as hub protein and associated with poor outcome in gastric and ovarian cancers [18] where OCSC are shown to be implicated in the progression of ovarian carcinoma and resistance to therapy [14–16]. Moreover, recently, ZNF521 was identified as one of the top 15 genes significantly correlated with the overall survival in 1692 serous ovarian cystadenocarcinomas [19]. Taken together the analyses of different public genomic databases indicate that ZNF521 is: i) amplified in 6% of ovarian carcinoma cases and ii) associated to poor survival in ovarian cancer patients [18–20] (S1 Fig).

Here, we highlight a new role of the transcriptional co-factor ZNF521 in OC. Overall, we found that higher levels of ZNF521 in HeyA8 and ES-2 human ovarian cancer cell lines enhances their growth (Fig 2), ability to migrate (Fig 3) and to form OC spheroids (Fig 4). Such a role of ZNF521 in hOC may be exerted via the modulated expression of several regulatory genes which are relevant in cancer [54,55] (Fig 5 and S1–S3 Tables).

qRT-PCR analysis confirmed the regulation by ZNF521 of a subset of these genes by ZNF521 (N = 7; Fig 6) that, once dysregulated, induce cellular transformation and tumorigenesis.

More in depth, the data presented so far demonstrate that ZNF521 is able to regulate the expression of HMMR (Hyaluronan-mediated motility receptor) [56–60], CTSK (Cathepsin K) [61–65], SAMD9 (Sterile Alpha Motif Domain-Containing Protein 9) [66,67], AIMP1 (Aminocyl-tRNA synthases interacting multi-functional protein 1) [68–71], PIBF1 (Progesterone-Induced Blocking Factor 1) [72–75], RB1CC1 (RB1-inducible coiled-coil 1) [76–78] and FXYD5 [79–81]. All these genes are well known to regulate tumour progression (proliferation, migration and metastasis) by regulating EMT pathway in cancers and are also linked to poor overall survival in different types of diseases.

Human OC HeyA8 and ES-2 cell lines overexpressing ZNF521 also increase their ability to form spheroids (enrichment of CSCs). CSCs have the ability to self-renew, differentiate and possess tumorigenic properties. CSCs are also involved in drug resistance, and it has been shown that some populations of CSCs share EMT-like cellular characteristics [82]. Indeed, whole-transcriptome profiling of OC cell lines confirmed the profound transcriptional impact of ZNF521 expression modulation on a set of genes involved in tumour growth, proliferation,
migration and metastasis. Forced ZNF521 expression altered the transcriptional profile of a total of 1375 and 742 genes in HeyA8 and in ES-2 human OC cell lines, respectively, as well as the enrichment of several cancer-related hallmarks including EMT regulatory genes.

Further in-depth analysis is necessary to better understand the molecular mechanism that underlines these activities of ZNF521 in human OC.

Taken together, these data are the first evidence of new role of the stem cell transcription co-factor ZNF521 (so far known for its involvement in the stem pathway) in the regulation of human epithelial ovarian carcinoma (hEOC) cells, suggesting that this could be due to the modulation exerted by ZNF521 on regulatory genes of the relevant molecular mechanisms of EMT in human ovarian cancer.

Supporting information

S1 Fig. Database analysis of ZNF521 expression in patients affected by ovarian cancer. Analysis of ZNF521 mutations in a set of 1025 patients [https://www.cbioportal.org] (A). Kaplan-Meier curve of overall survival of 655 patients [http://kmplot.com] (B).

(TIF)

S1 Table. Differentially expressed genes (DEGs) in HeyA8 (A) and ES-2 (B) OC cell lines with fold change and p-value.

(XLSX)

S2 Table. Hallmarks of cancer enriched in DEGs of HeyA8 (A), ES-2 (B) ZNF521 over-expressing cells, and in 106 overlapping DEGs (C).

(XLSX)

S3 Table. Normalized expression counts of DEGs specifically involved in growth, metastasis, migration and proliferation in hOC cell lines analysed.

(XLSX)

S1 Raw image.

(TIF)
Acknowledgments

This paper is in memory of Professor Giovanni Morrone (who conceived the work) and Doctor Heather Mandy Bond (who supervised all the experimental work and wrote the original draft of the manuscript) two dear friends, exceptional scientists and great mentors.

Author Contributions

Conceptualization: Stefania Scicchitano, Maria Mesuraca.

Data curation: Stefania Scicchitano, Ylenia Montalcini, Valeria Lucchino, Valentina Melocchi, Valerio Gigantino, Emanuela Chiarella.

Formal analysis: Stefania Scicchitano, Ylenia Montalcini, Valentina Melocchi, Fabrizio Bianchi.

Investigation: Stefania Scicchitano, Ylenia Montalcini.

Project administration: Alessandro Weisz, Maria Mesuraca.

Supervision: Maria Mesuraca.

Validation: Stefania Scicchitano, Maria Mesuraca.

Visualization: Stefania Scicchitano, Maria Mesuraca.

Writing – original draft: Stefania Scicchitano, Maria Mesuraca.

Writing – review & editing: Stefania Scicchitano, Valentina Melocchi, Fabrizio Bianchi, Alessandro Weisz, Maria Mesuraca.

References

1. McMullen M, Karakasis K, Rottapel R, Oza AM. Advances in ovarian cancer, from biology to treatment. Nat Cancer. 2021; 2(1):6–8. https://doi.org/10.1038/s43018-020-00166-5 PMID: 35121897

2. Reid BM, Permutt JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1):9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084 PMID: 28443200

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7–30. https://doi.org/10.3322/caac.21332 PMID: 26742998

4. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther. 2013 Aug; 139(2):95–110. https://doi.org/10.1016/j.pharmthera.2013.02.003 PMID: 23458608

5. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014; 384(9951):1376–1388. https://doi.org/10.1016/S0140-6736(13)62146-7 PMID: 24767708

6. Hennessy BT, Mills GB. Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling. Int J Biochem Cell Biol. 2006; 38(9):1450–1456. https://doi.org/10.1016/j.biocel.2006.01.009 PMID: 16682246

7. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64(21):7678–7681. https://doi.org/10.1158/0008-5472.CAN-04-2933 PMID: 15520168

8. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007; 448(7152):439–444. https://doi.org/10.1038/nature05933 PMID: 17611497

9. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609–615. https://doi.org/10.1038/nature10166 Erratum in: Nature. 2012; 490(7419):298. PMID: 21720365.

10. Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, et al. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Gynecol Oncol. 2021; 160(3):786–792. https://doi.org/10.1016/j.ygyno.2020.12.007 PMID: 33375991

11. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005; 18 Suppl 2:S19–S32. https://doi.org/10.1038/modpathol.3800306 PMID: 15761464
Shih IeM Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511–1518. https://doi.org/10.1016/s0002-9440(10)63708-x PMID: 15111296

Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009; 4:287–313. https://doi.org/10.1146/annurev.pathol.4.110807.092246 PMID: 18842102

Lupia M, Angiolini F, Bertalot G, Freddi S, Sachsenmeier KF, Chisci E, et al. CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. Stem Cell Reports. 2018; 10; 10(4):1412–1425. https://doi.org/10.1016/j.stemcr.2018.02.009 PMID: 29551673

Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010; 102(8):1276–1283. https://doi.org/10.1038/sj.bjc.6606526 PMID: 20354527

Pieterse Z, Amaya-Padilla MA, Singomat T, Binju M, Madjid BD, Yu Y, et al. Ovarian cancer stem cells and their role in drug resistance. Int J Biochem Cell Biol. 2019; 106:117–126. https://doi.org/10.1016/j.biocel.2018.11.012 PMID: 30508594

Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009; 6(2):e24. https://doi.org/10.1371/journal.pmed.1000024 PMID: 19192944

Zhao F, Yu YQ. The prognostic roles of mRNAs of the exosomes derived from bone marrow stromal cells in common malignancies: a bioinformatic study. Onco Targets Ther. 2018; 11:7979–7986. https://doi.org/10.2147/OTT.S172414 PMID: 30519039

An Y, Yang Q. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis. Biomed Res Int. 2020; 2020:7594098. https://doi.org/10.1155/2020/7594098 PMID: 33831581

cBiportal For Cancer Genomics. Available online: https://www.cbioportal.org.

Li Z, Fu X, Wu W, Liu Z, Chen Z, Zhou C, et al. Zfp521 is essential for the quiescence and maintenance of adult hematopoietic stem cells under stress. iScience. 2021; 24(2):102039. https://doi.org/10.1016/j.isci.2021.102039 PMID: 33532716

Mesuraca M, Amodio N, Chiarella E, Scicchitano S, Aloisio A, Codispoti B, et al. Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches. Molecules. 2018; 23(8):2060. https://doi.org/10.3390/molecules23082060 PMID: 30126100

Mesuraca M, Chiarella E, Scicchitano S, Codispoti B, Giordano M, Nappo G, et al. ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid Malignancies. Biomed Res Int 2020; 2020:7594098. https://doi.org/10.1155/2020/7594098 PMID: 33831581

Prange KHM, Mandoli A, Kuznetsova T, Wang SY, Sotoca AM, Marneth AE, et al. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Oncogene. 2017; 36(23):3346–3356. https://doi.org/10.1038/onc.2016.488 PMID: 28114278

Chiarella E, Aloisio A, Scicchitano S, Todoerti K, Cosentino EG, Lico D, et al. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape. Int J Mol Sci. 2021; 22(19):10814. https://doi.org/10.3390/ijms221910814 PMID: 34639154

Kamiya D, Banno S, Sasai N, Ohgushi M, Inomata H, Watanabe K, et al. Intrinsic transition of embryonic stem-cell differentiation into neural progenitors. Nature. 2011; 470(7335):503–509. https://doi.org/10.1038/nature09726 PMID: 21326203

Spina R, Filocamo G, Iaccino E, Scicchitano S, Lupia M, Chiarella E, et al. Critical role of zinc finger protein 521 in the control of growth, clonogenicity and tumorigenic potential of medulloblastoma cells. Oncotarget. 2013; 4(8):1280–1292. https://doi.org/10.18632/oncotarget.1176 PMID: 23907569

Scicchitano S, Giordano M, Lucchino V, Montalcini Y, Chiarella E, Aloisio A, et al. The stem cell-associated transcription co-factor, ZNF521, interacts with GLI1 and GLI2 and enhances the activity of the Sonic hedgehog pathway. Cell Death Dis. 2019; 10(10):715. https://doi.org/10.1038/s41419-019-1946-x PMID: 31558698

Chiarella E, Lombardo N, Lobello N, Aloisio A, Aragona T, Pelaia C, et al. Nasal Polyposis: Insights in Epithelial-Mesenchymal Transition and Differentiation of Polyp Mesenchymal Stem Cells. Int J Mol Sci. 2020; 21(18):6878. https://doi.org/10.3390/ijms21186878 PMID: 32961745

Chiarella E, Aloisio A, Scicchitano S, Lucchino V, Montalcini Y, Galasso O, et al. ZNF521 Represses Osteoblastic Differentiation in Human Adipose-Derived Stem Cells. Int J Mol Sci. 2018; 19(12):4095. https://doi.org/10.3390/ijms19124095 PMID: 30567301
ZNF521 induces an aggressive phenotype in human ovarian carcinoma

31. Kang S, Akerblad P, Kirvanta R, Gupta RK, Kajimura S, Griffin MJ, et al. Regulation of early adipose commitment by Zfp521. PLoS Biol. 2012; 10(11):e1001433. https://doi.org/10.1371/journal.pbio.1001433 PMID: 23029378

32. Mesuraca M, Galasso O, Guido L, Chiarella E, Sicchitano S, Vatrinet R, et al. Expression profiling and functional implications of a set of zinc finger proteins, ZNF423, ZNF470, ZNF521, and ZNF780β, in primary osteoarthritic articular chondrocytes. Mediators Inflamm. 2014; 2014:318793. https://doi.org/10.1155/2014/318793 PMID: 24976683

33. Hesse E, Kirvanta R, Wu M, Saito H, Yamana K, Correa D, et al. Zinc finger protein 521, a new player in bone formation. Ann N Y Acad Sci. 2010; 1192:32–7. https://doi.org/10.1111/j.1749-6632.2009.05347.x PMID: 20392215

34. Wu M, Hesse E, Morvan F, Zhang JP, Correa D, Rowe GC, et al. Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivo. Bone. 2009; 44(4):528–536. https://doi.org/10.1016/j.bone.2008.11.011 PMID: 19095088

35. Chiarella E, Aloisio A, Sicchitano S, Bond HM, Mesuraca M. Regulatory Role of microRNAs Targeting the Transcription Co-Factor ZNF521 in Normal Tissues and Cancers. Int J Mol Sci. 2021; 22(18):4861. https://doi.org/10.3390/ijms22184861 PMID: 34445164

36. Han R, Kan Q, Sun Y, Wang S, Zhang G, Peng T, et al. MiR-9 promotes the neural differentiation of mouse bone marrow mesenchymal stem cells via targeting zinc finger protein 521. Neurosci Lett. 2012; 515(2):147–152. https://doi.org/10.1016/j.neulet.2012.03.032 PMID: 22465325

37. Strumidło A, Skiba S, Rubiński J. The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation. Hered Cancer Clin Pract. 2017; 15:15. https://doi.org/10.1186/s13053-017-0076-7 PMID: 29021870

38. Huan C, Xiao Xu C, Xifang R. Zinc Finger Protein 521, Negatively Regulated by MicroRNA-204-5p, Promotes Proliferation, Motility and Invasion of Gastric Cancer Cells. Technol Cancer Res Treat. 2019; 18:1533033619874783. https://doi.org/10.1177/1533033619874783 PMID: 31526099

39. Yang N, Wang L, Chen T, Liu R, Liu Z, Zhang L. ZNF521 which is downregulated by miR-802 suppresses malignant progression of Hepatocellular Carcinoma through regulating Runx2 expression. J Cancer. 2020; 11(19):5831–5839. https://doi.org/10.7150/jca.45190 PMID: 32913476

40. La Rocca R, Fulciniti M, Lakshminanth T, Mesuraca M, Hassan TA, et al. Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells. J Immunol. 2009 15; 182(6):4529–4537. https://doi.org/10.4049/jimmunol.0802109 PMID: 19342626

41. Bernaudo F, Monteleone F, Mesuraca M, Krishnan S, Chiarella E, Sicchitano S, et al. Validation of a novel shotgun proteomic workflow for the discovery of protein-protein interactions: focus on ZNF521. J Proteome Res. 2015; 14(4):1888–1899. https://doi.org/10.1021/pr501288h PMID: 25774817

42. Codispoti B, Rinaldo N, Chiarella E, Lupia M, Spoleti CB, Marafioti MG, et al. Recombinant TAT-BMI-1 fusion protein induces ex vivo expansion of human umbilical cord blood-derived hematopoietic stem cells. OncoTargets. 2017; 8(27):43782–43798. https://doi.org/10.18632/oncotarget.15156 PMID: 28187482

43. Lobello N, Biamonte F, Pisanu ME, Faniello MC, Jakopin Ž, Chiarella E, et al. Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition. OncoTargets. 2016; 7(38):62019–62033. https://doi.org/10.18632/oncotarget.11495 PMID: 27566559

44. Nassa G, Salvati A, Tarallo R, Gigantino V, Alexandrova E, Memoli D, et al. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells. Sci Adv. 2019; 5(2):eaav5590. https://doi.org/10.1126/sciadv.aav5590 PMID: 30755443

45. Tarallo R, Giurato G, Bruno G, Ravo M, Rizzato F, Salvati A, et al. The nuclear receptor ERβ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading. Genome Biol. 2017; 18(1):189. https://doi.org/10.1186/s13059-017-1321-0 PMID: 29017520

46. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29(1):15–21. Available from: https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/bts639 PMID: 23104886

47. Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550; Available from: http://genomediscussion.biomedcentral.com/articles/10.1186/s13059-014-0550-8 PMID: 25516281

48. Liberzon A, Birger C., Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1(6),417–425; https://doi.org/10.1016/j.cels.2015.12.004 PMID: 26771021

49. Faniello MC, Di Sanzo M, Quaresima B, Baudi F, Di Caro V, Cuda G, et al. p53-mediated downregulation of H ferritin promoter transcriptional efficiency via NF-Y. Int J Biochem Cell Biol. 2008; 40(10):2110–9. https://doi.org/10.1016/j.biocell.2008.02.016 PMID: 18372207
50. Chiarella E, Codispoti B, Aloisio A, Cosentino EG, Scicchitano S, Montalcini Y, et al. Zoledronic acid inhibits the growth of leukemic MLL-AF9 transformed hematopoietic cells. Heliyon. 6(6),e04020; https://doi.org/10.1016/j.heliyon.2020.e04020 PMID: 32529062

51. Kaplan-Meier Plotter–Ovarian Cancer. Available online: http://kmplot.com/analysis/index.php?p=service&cancer=ovar#.

52. Gyorffy B, Lángczyk A, Szálási Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19(2):197–208. https://doi.org/10.1530/ERC-11-0329 PMID: 22277193

53. Ma Y, Wang X, Qiu C, Qin J, Wang K, Sun G, et al. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer. Cancer Sci. 2021; 112(2):537–549. https://doi.org/10.1111/cas.14732 PMID: 33185955

54. Petrillo M, Nero C, Amadio G, Gallo D, Fagotti A, Scambia G. Targeting the hallmarks of ovarian cancer: The big picture. Gynecol Oncol. 2016; 142(1):176–183. https://doi.org/10.1016/j.ygyno.2016.03.037 PMID: 27058837

55. López-Reig R, López-Guerrero JA. The hallmarks of ovarian cancer: proliferation and cell growth. EJC Suppl. 2020; 15:27–37. https://doi.org/10.1016/j.ejcsup.2019.12.001 PMID: 33240440

56. Zhang D, Liu J, Xie T, Jiang Q, Ding L, Zhu J, et al. Oleate acid-stimulated HMMR expression by CEBPα is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma. Int J Biol Sci. 2020; 16(15):2812–2827. https://doi.org/10.7150/ijbs.49785 PMID: 33061798

57. Sun H, Ma L, Chen J. Hyaluronan-mediated motility receptor expression functions as a prognostic biomarker in uterine carcinosarcoma based on bioinformatics analysis. J Int Med Res. 2021; 49 (6):30006521012043. https://doi.org/10.1177/03000605211020143 PMID: 34111996

58. Guo H, Fan Q. Identification of the HMMR Gene as a Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma Based on Integrated Bioinformatics Analysis. Evid Based Complement Alternat Med. 2021; 2021:5970085. https://doi.org/10.1155/2021/5970085 PMID: 34221079

59. Lu XQ, Zhang JQ, Zhang SX, Qiao J, Qiu MT, Liu XR, et al. Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis. BMC Cancer. 2021; 21(1):697. https://doi.org/10.1186/s12885-021-08358-7 PMID: 34126961

60. Lei X, Zhang M, Guan B, Chen Q, Dong Z, Wang C. Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis. Hum Genomics. 2021; 15(1):39. https://doi.org/10.1186/s40246-021-00341-4 PMID: 34187556

61. Tan GJ, Peng ZK, Lu JP, Tang FQ. Cathepsin mediate tumor metastasis. World J Biol Chem. 2013; 4 (4):91–101. https://doi.org/10.4331/wjbc.v4.i4.91 PMID: 24340132

62. Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007; 67(20):9894–9902. https://doi.org/10.1158/0008-5472.CAN-06-3940 PMID: 17942921

63. Xu H, Ma Y, Zhang Y, Pan Z, Lu Y, Liu P, et al. Identification of Cathepsin K in the Peritoneal Metastasis of Ovarian Carcinoma Using In-silico, Gene Expression Analysis. J Cancer. 2016; 7(6):722–9. https://doi.org/10.7150/jca.14277 PMID: 27076854

64. Fan X, Wang C, Song X, Liu H, Li X, Zhang Y. Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer. Histol Histopathol. 2018; 33(7):673–680. https://doi.org/10.14670/HH-11-960 PMID: 29303207

65. Vashum Y, PremSingh R, Kottaiswamy A, Soma M, Padmanaban A, Kalaivelan P, et al. Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro. Mol Biol Rep. 2021; 48(1):105–116. https://doi.org/10.1007/s10789-020-05951-0 PMID: 33294960

66. Ma W, Zhang K, Bao Z, Jiang T, Zhang Y. SAMD9 Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma. Front Immunol. 2021; 12:659659. https://doi.org/10.3389/fimmu.2021.659659 PMID: 33936093

67. Yoshida M, Tanase-Nakao K, Shima H, Shirai R, Yoshida K, Osumi T, et al. Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7. Br J Haematol. 2020; 191(5):835–843. https://doi.org/10.1111/bjh.17006 PMID: 32709848

68. Zhou Z, Sun B, Huang S, Yu D, Zhang X. Roles of aminocyl-tRNA synthetase-interacting multifunctional proteins in physiology and cancer. Cell Death Dis. 2020; 11(7):579. https://doi.org/10.1038/s41419-020-02794-2 PMID: 32709848

69. Kwon HS, Park MC, Kim DG, Cho K, Park YW, Han JM, et al. Identification of CD23 as a functional receptor for the proinflammatory cytokine AIMP1/p43. J Cell Sci. 2012; 125(Pt 19):4620–4629. https://doi.org/10.1242/jcs.108209 PMID: 22767513
70. Gao W, An C, Xue X, Zheng X, Niu M, Zhang Y, et al. Mass Spectrometric Analysis Identifies AIMP1 and LT4H as FSCN1-Binding Proteins in Laryngeal Squamous Cell Carcinoma. Proteomics. 2019; 19 (21–22):e1900059. https://doi.org/10.1002/pmic.201900059 PMID: 31287215

71. Tian Y, Wang J, Qin C, Zhu G, Chen X, Chen Z, et al. Identifying 8-mRNA si Based Signature for Predicting Survival in Patients With Head and Neck Squamous Cell Carcinoma via Machine Learning. Front Genet. 2020; 11:566159. https://doi.org/10.3389/fgene.2020.566159 PMID: 33329703

72. Huang B, Faucette AN, Pawlitz MD, Pei B, Goyert JW, Zhou JZ, et al. Interleukin-33-induced expression of PIBF1 by decidual B cells protects against preterm labor. Nat Med. 2017; 23(1):128–135. https://doi.org/10.1038/nm.4244 PMID: 27918564

73. Ro EJ, Ryu SH, Park EY, Ryu JW, Byun SJ, Heo SH, et al. PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells. Breast Cancer Res Treat. 2020; 182(3):591–600. https://doi.org/10.1007/s10549-020-05732-0 PMID: 32529408

74. Madendag Y, Sahin E, Madendag IC, Sahin ME, Acmaiz G, Karaman H. High Immune Expression of Progesterone-Induced Blocking Factor in Epithelial Ovarian Cancer. Technol Cancer Res Treat. 2018; 17:15333818783911. https://doi.org/10.1177/1533033818783911 PMID: 29962287

75. Balassa T, Berta G, Jakab L, Bohonyi N, Szekeres-Bartho J. The effect of the Progesterone-Induced Blocking Factor (PIBF) on E-cadherin expression, cell motility and invasion of primary tumour cell lines. J Reprod Immunol. 2018; 128:128–15. https://doi.org/10.1016/j.jri.2017.10.047 PMID: 29107859

76. Ikebuchi K, Chano T, Ochi Y, Tameno H, Shimada T, Hisa Y, et al. RB1CC1 activates the promoter and expression of RB1 in human cancer. Int J Cancer. 2009; 125(4):861–867. https://doi.org/10.1002/ijc.24466 PMID: 19437535

77. Vu TT, Stölzel F, Wang KW, Röllig C, Tursky ML, Molloy TJ, et al. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia. Leukemia. 2021; 35(7):1933–1948. https://doi.org/10.1038/s41375-020-01095-z PMID: 33262524

78. Yeo SK, Paul R, Haas M, Wang C, Guan JL. Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer. Autophagy. 2018; 14 (7):1214–1225. https://doi.org/10.1080/15548627.2018.1460010 PMID: 29938573

79. Tassi RA, Gambino A, Ardighieri L, Bignotti E, Todeschini P, Romani C, et al. FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. Br J Cancer. 2019; 121(7):584–592. https://doi.org/10.1038/s41416-019-0553-z PMID: 31434988

80. Liu YK, Jia YJ, Liu SH, Shi HJ, Ma J. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells. Histol Histopathol. 2021; 36(5):535–545. https://doi.org/10.14670/HH-18-310 PMID: 33570156

81. Bai Y, Li LD, Li J, Chen RF, Yu HL, Sun HF, et al. A FXYD5/TGF-β/SMAD positive feedback loop drives epithelial-to-mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. Int J Oncol. 2020; 56(1):301–314. https://doi.org/10.3892/ijo.2019.4911 PMID: 31746425

82. Tanabe S, Quader S, Cabral H, Ono R. Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies. Front Pharmacol. 2020. 17; 11:904. https://doi.org/10.3389/fphar.2020.00904 PMID: 32625096